Researchers have generated preclinical data demonstrating that the protein KDM1, which functions as a lysine demethylase, is a potential target for glioma treatment, according to new research.
Researchers have generated preclinical data demonstrating that the protein KDM1, which functions as a lysine demethylase, is a potential target for glioma treatment, according to new research.